Shares of several vaccine makers soared after reports suggest that the Biden administration is in discussions with Moderna MRNA and Pfizer PFE to set up a possible vaccine program aimed at preventing ...

The health secretary is frequently returning to rhetoric from his time as one of the nation's most prominent vaccine critics.

The HHS chief, who has long argued that vaccines cause autism, dismissed the notion that "better diagnoses, better recognition, or changing diagnostic criteria" are driving up figures. Also, the CDC's ...

Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Novavax (NVAX – Research Report) today and set a price target of ...

Complex Pandemic Accord negotiations have been under way since 2021, with 13 formal meetings and numerous informal sessions.

Yesterday, the US Centers for Disease Control and Prevention (CDC) issued a level 2 travel notice (practice enhanced ...

Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. Read ...

Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, ...

An advisory panel on vaccines meets, carefully, in the shadow of a health secretary who has often criticized it.

As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...

Sanofi’s next-generation experimental asthma drug failed to significantly reduce flare-ups in patients with ...